Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,741,712
  • Shares Outstanding, K 211,010
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.84
  • Price/Sales 5.10
  • Price/Cash Flow 11.27
  • Price/Book 4.59

Price Performance

See More
Period Period Low Period High Performance
1-Month
276.65 +7.01%
on 05/23/18
310.91 -4.78%
on 06/13/18
+16.35 (+5.85%)
since 05/22/18
3-Month
249.17 +18.81%
on 04/24/18
310.91 -4.78%
on 06/13/18
+24.15 (+8.88%)
since 03/22/18
52-Week
249.17 +18.81%
on 04/24/18
370.57 -20.11%
on 01/26/18
+15.47 (+5.51%)
since 06/22/17

Most Recent Stories

More News
Sarepta Pharma Pushes Two Biotech ETFs to New Highs

The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

BBP : 45.46 (+0.38%)
SLDB : 42.07 (-0.64%)
BBC : 34.27 (-0.49%)
SBIO : 38.82 (+0.15%)
SRPT : 140.33 (-6.23%)
IBB : 112.23 (-0.34%)
VRTX : 159.19 (+1.67%)
ALNY : 104.20 (+1.47%)
XBI : 99.08 (+0.02%)
ALXN : 127.57 (+1.40%)
BIIB : 296.04 (-0.44%)
Sarepta Pharma Pushes Two Biotech ETFs to New Highs

The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

BBP : 45.46 (+0.38%)
SLDB : 42.07 (-0.64%)
BBC : 34.27 (-0.49%)
SBIO : 38.82 (+0.15%)
SRPT : 140.33 (-6.23%)
IBB : 112.23 (-0.34%)
VRTX : 159.19 (+1.67%)
ALNY : 104.20 (+1.47%)
XBI : 99.08 (+0.02%)
ALXN : 127.57 (+1.40%)
BIIB : 296.04 (-0.44%)
Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018

Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday, June 28, 2018. The live webcast will be from 8:00-9:00...

BIIB : 296.04 (-0.44%)
PTC Therapeutics' Spinal Muscular Atrophy Study Successful

PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.

PTCT : 36.01 (-0.83%)
AGLE : 10.72 (+2.29%)
RHHBY : 27.7700 (+2.51%)
BIIB : 296.04 (-0.44%)
Biogen Foundation Selects Grantees to Receive $10 Million Investment for STEM Education

The Biogen Foundation today announced the six nonprofits that will share a previously-announced four-year, $10 million grant to drive the development of local STEM (science, technology, engineering, and...

BIIB : 296.04 (-0.44%)
SmarTrend Watching for Potential Rebound in Shares of Biogen Inc After 5.65% Loss

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $283.24 to a high of $294.97. Yesterday, the shares fell 5.7%, which took the trading range below the 3-day low of $303.42...

BIIB : 296.04 (-0.44%)
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus

Roche (RHHBY) announced positive long-term data on leukemia drug Gazyva and MS drug Ocrevus.

NVS : 75.06 (+1.46%)
RHHBY : 27.7700 (+2.51%)
AMGN : 185.15 (-0.45%)
BIIB : 296.04 (-0.44%)
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

CELG : 78.80 (-0.43%)
LCI : 14.05 (+0.36%)
GILD : 71.07 (-0.63%)
VRX : 24.27 (-1.82%)
BIIB : 296.04 (-0.44%)
Drug Stocks: The Next Hot Industry or Value Traps?

These 5 stocks look dirt cheap but is it too good to be true?

CELG : 78.80 (-0.43%)
LCI : 14.05 (+0.36%)
GILD : 71.07 (-0.63%)
VRX : 24.27 (-1.82%)
BIIB : 296.04 (-0.44%)
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

AXON : 2.41 (-9.74%)
REGN : 331.97 (+0.89%)
AMGN : 185.15 (-0.45%)
ALXN : 127.57 (+1.40%)
BIIB : 296.04 (-0.44%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 299.85
1st Resistance Point 297.95
Last Price 296.04
1st Support Level 294.57
2nd Support Level 293.09

See More

52-Week High 370.57
Fibonacci 61.8% 324.20
Fibonacci 50% 309.87
Last Price 296.04
Fibonacci 38.2% 295.54
52-Week Low 249.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar